Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Mycophenolate mofetil--a new immunosuppressive agent]

S Bergan1, D Albrechtsen, P Fauchald

  • 1Institutt for klinisk biokjemi, Rikshospitalet, Oslo.

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|August 30, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma concentration of atorvastatin metabolites correlates with low-density lipoprotein cholesterol reduction in patients with coronary heart disease.

Pharmacology research & perspectives·2023
Same author

Costimulation Blockade: America First, Canada Second … What About Norway?

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Quality of life in kidney donors.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
Same author

IMP dehydrogenase basal activity in MOLT-4 human leukaemia cells is altered by mycophenolic acid and 6-thioguanosine.

Scandinavian journal of clinical and laboratory investigation·2008
Same author

Optimisation of azathioprine immunosuppression after organ transplantation by pharmacological measurements.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

The potential impact of environmental variation on the concentrations and ecological effects of pollutants in a marine avian top predator.

Environment international·2007
Same journal

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

Correction: Management of acute epistaxis.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

A woman in her 70s with chest pain and elevated troponin T levels.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

More systematic follow-up after childbirth.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
See all related articles

Mycophenolate mofetil reduces early renal transplant rejection but increases side effects. Long-term graft survival remains similar across treatments, suggesting potential use in high-risk patients.

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation Medicine

Background:

  • Mycophenolate mofetil (MMF) is an immunosuppressant prodrug.
  • It converts to mycophenolic acid, inhibiting inosine monophosphate dehydrogenase.
  • This depletes purine synthesis, affecting lymphocyte proliferation.

Purpose of the Study:

  • To evaluate the efficacy and safety of MMF in renal allograft recipients.
  • To assess its impact on rejection rates and graft survival.

Main Methods:

  • Three randomized, double-blind, multicenter trials were conducted.
  • Renal allograft recipients were assigned to MMF or control groups.
  • Outcomes included rejection rates, adverse events, and graft survival.

Related Experiment Videos

Main Results:

  • MMF demonstrated lower early rejection rates in the first months post-transplantation.
  • Increased frequency of side effects, including leucopenia and gastrointestinal issues, was observed.
  • At 12 months, no significant difference in graft survival was found between groups.

Conclusions:

  • MMF effectively reduces early renal allograft rejection.
  • Adverse events and increased infection/malignancy risk are associated with MMF.
  • Its role may be specific to high-risk transplant recipients, pending further evaluation.